Stoke (STOK) CMO reports insider sales; holds 7,195 shares

Stoke Therapeutics (STOK) disclosed insider sales by its Chief Medical Officer on 11/03/2025 under a pre‑arranged Rule 10b5-1 trading plan adopted on December 11, 2024.

Rhea-AI Filing Summary

Stoke Therapeutics (STOK) disclosed insider sales by its Chief Medical Officer on 11/03/2025 under a pre‑arranged Rule 10b5-1 trading plan adopted on December 11, 2024. The transactions included 3,776 shares at a weighted average price of $25.2242 (range $24.74–$25.65), 1,455 shares at $26.0206 (range $25.79–$26.50), 600 shares at $27.54 (range $27.40–$27.60), and 100 shares at $29.35.

Following these sales, the reporting person directly beneficially owned 7,195 shares.

Insider Trade Summary

Net Seller: 5,931 shares

Net Sell 4 txns

Insider Ticho Barry

Role CHIEF MEDICAL OFFICER

Sold 5,931 shs ($153K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,776	$25.2242	$95K
Sale	Common Stock	1,455	$26.0206	$38K
Sale	Common Stock	600	$27.54	$17K
Sale	Common Stock	100	$29.35	$3K

Holdings After Transaction: Common Stock — 7,195 shares (Direct)

Footnotes (4)

1. F1. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.74 to $25.65 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 4.
3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.79 to $26.50 per share, inclusive.
4. F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.40 to $27.60 per share, inclusive.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did STOK report?

The Chief Medical Officer reported multiple stock sales on 11/03/2025 under a Rule 10b5-1 trading plan.

How many STOK shares did the insider sell and at what prices?

Sales were 3,776 at $25.2242 (range $24.74–$25.65), 1,455 at $26.0206 (range $25.79–$26.50), 600 at $27.54 (range $27.40–$27.60), and 100 at $29.35.

What is the insider’s remaining STOK ownership?

After the reported transactions, the insider directly beneficially owned 7,195 shares.

Was a 10b5-1 plan used for these sales?

Yes. The filing states the trades were made under a Rule 10b5-1 plan adopted on December 11, 2024.

What is the insider’s role at Stoke Therapeutics (STOK)?

The reporting person serves as Chief Medical Officer.

Were the reported prices single trades or averages?

They are weighted average prices; shares were sold in multiple transactions within the stated ranges.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/05/2025 - 04:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ticho Barry

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/03/2025		S(1)		3,776	D	$25.2242(2)	9,350	D
Common Stock	11/03/2025		S(1)		1,455	D	$26.0206(3)	7,895	D
Common Stock	11/03/2025		S(1)		600	D	$27.54(4)	7,295	D
Common Stock	11/03/2025		S(1)		100	D	$29.35	7,195	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.74 to $25.65 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 4.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.79 to $26.50 per share, inclusive.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.40 to $27.60 per share, inclusive.

	/s/ Jonathan Allan, Attorney-in-Fact	11/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.